KGK Sciences

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started recruiting participants for the first-ever clinical trial assessing the effects of psilocybin in adults diagnosed with Fragile X Syndrome (FXS), the leading genetic...

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder. KGK and its client Nova Mentis (OTC: NMLSF) are set to conduct this pioneering...

Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry, manufacturing and controls (CMC) published guidelines. NOVA’s new compounds would be used in...

Wellbeing Digital Sciences Inc. (OTC: KONEF) filed its financial results for the quarter ended July 31, 2022 and provided some insight on their most recent businesses. Numbers for the selected period showed: Total revenue of $872.731 (CA$1,160,547), representing a 2.5% increase compared to...